{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T15:00:30Z","timestamp":1786806030997,"version":"build-2736575974"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"DOI":"10.3389\/fpsyt.2019.00017","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T04:25:26Z","timestamp":1548908726000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":120,"title":["The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder"],"prefix":"10.3389","volume":"10","author":[{"given":"Bing","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehala","family":"Subramaniapillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yena","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Iacobucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo B.","family":"Mansur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Vos","year":"2017","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4088\/JCP.14m09298","article-title":"The economic burden of adults with major depressive disorder in the United States (2005 and 2010)","volume":"76","author":"Greenberg","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9758\/cpn.2016.14.1.1","article-title":"Cognitive deficits as a mediator of poor occupational function in remitted major depressive disorder patients","volume":"14","author":"Woo","year":"2016","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"B4","volume-title":"Diagnostic and Statistical Manual of Mental Disorder","year":"2013"},{"key":"B5","unstructured":"Definitions of the RDoC Domains and Constructs2018"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.2174\/1381612823666170111144340","article-title":"Role of proinflammatory cytokines in dopaminergic system disturbances, implications for anhedonic features of MDD","volume":"23","author":"Pan","year":"2017","journal-title":"Curr Pharm Des."},{"key":"B7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jad.2006.08.020","article-title":"The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton Pleasure Scale (SHAPS)","volume":"99","author":"Franken","year":"2007","journal-title":"J Affect Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.psychres.2007.05.010","article-title":"Implications of the DSM's emphasis on sadness and anhedonia in major depressive disorder","volume":"159","author":"Buckner","year":"2008","journal-title":"Psychiatry Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.beth.2016.09.009","article-title":"An exploratory randomized controlled trial of personalized lifestyle advice and tandem skydives as a means to reduce anhedonia","volume":"48","author":"Van Roekel","year":"2017","journal-title":"Behav Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S505","DOI":"10.1016\/j.euroneuro.2012.07.004","article-title":"Anhedonia and major depression: the role of agomelatine","volume":"22","author":"Di Giannantonio","year":"2012","journal-title":"Eur Neuropsychopharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1177\/0269881114568041","article-title":"Neural correlates of change in major depressive disorder anhedonia following open-label ketamine","volume":"29","author":"Lally","year":"2015","journal-title":"J Psychopharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1517\/14740338.2015.1046836","article-title":"Vortioxetine: a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder","volume":"14","author":"Al-Sukhni","year":"2015","journal-title":"Expert Opin Drug Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"pyw055","DOI":"10.1093\/ijnp\/pyw055","article-title":"The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials","volume":"19","author":"McIntyre","year":"2016","journal-title":"Int J Neuropsychopharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.2147\/NDT.S150589","article-title":"The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone","volume":"13","author":"McIntyre","year":"2017","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B15","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jad.2017.11.081","article-title":"Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: a novel dual outcome measure in depressive disorders","volume":"227","author":"Christensen","year":"2018","journal-title":"J Affect Disord."},{"key":"B16","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12888-014-0276-x","article-title":"Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials","volume":"14","author":"Berhan","year":"2014","journal-title":"BMC Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jad.2016.07.015","article-title":"A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms","volume":"206","author":"Baldwin","year":"2016","journal-title":"J Affect Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.euroneuro.2016.03.007","article-title":"A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults","volume":"26","author":"Thase","year":"2016","journal-title":"Eur Neuropsychopharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eurpsy.2017.02.485","article-title":"Anhedonia predicts poor psychosocial functioning: results from a large cohort of patients treated for major depressive disorder by general practitioners","volume":"44","author":"Vinckier","year":"2017","journal-title":"Eur Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1038\/npp.2015.75","article-title":"Common and dissociable dysfunction of the reward system in bipolar and unipolar depression","volume":"40","author":"Satterthwaite","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1177\/0269881113494104","article-title":"Anhedonia revisited: is there a role for dopamine-targeting drugs for depression?","volume":"27","author":"Argyropoulos","year":"2013","journal-title":"J Psychopharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/hup.2557","article-title":"Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study","volume":"31","author":"Gargoloff","year":"2016","journal-title":"Hum Psychopharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0924-9338(11)72356-2","article-title":"Major depressive disorder, anhedonia and agomelatine: an open-label study","volume":"25","author":"Di Giannantonio","year":"2011","journal-title":"J Biol Regul Homeost Agents"},{"key":"B24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/JCP.0b013e31825d6c25","article-title":"Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study","volume":"32","author":"Martinotti","year":"2012","journal-title":"J Clin Psychopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"pyw003","DOI":"10.1093\/ijnp\/pyw003","article-title":"Agomelatine increases BDNF serum levels in depressed patients in correlation with the improvement of depressive symptoms","volume":"19","author":"Martinotti","year":"2016","journal-title":"Int J Neuropsychopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0188043","DOI":"10.1371\/journal.pone.0188043","article-title":"Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression","volume":"12","author":"Burstein","year":"2017","journal-title":"PLoS ONE"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1017\/S1461145713000679","article-title":"Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial","volume":"16","author":"Corruble","year":"2013","journal-title":"Int J Neuropsychopharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fpsyt.2011.00010","article-title":"Anhedonia and substance dependence: clinical correlates and treatment options","volume":"2","author":"Hatzigiakoumis","year":"2011","journal-title":"Front Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.psychres.2017.02.027","article-title":"Cannabis use and the course and outcome of major depressive disorder: a population based longitudinal study","volume":"251","author":"Feingold","year":"2017","journal-title":"Psychiatry Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.nbd.2012.05.007","article-title":"Neurogenetics of depression: a focus on reward processing and stress sensitivity","volume":"52","author":"Bogdan","year":"2013","journal-title":"Neurobiol Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jpsychires.2007.09.004","article-title":"Remission in depressed outpatients: more than just symptom resolution?","volume":"42","author":"Zimmerman","year":"2008","journal-title":"J Psychiatr Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jad.2017.11.003","article-title":"Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: a systematic review","volume":"227","author":"Lee","year":"2018","journal-title":"J Affect Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1017\/S1092852915000826","article-title":"Treating to target in major depressive disorder: response to remission to functional recovery","volume":"20","author":"McIntyre","year":"2015","journal-title":"CNS Spectr."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1092852917000761","article-title":"Efficacy of vortioxetine in working patients with generalized anxiety disorder","author":"Christensen","year":"2017","journal-title":"CNS Spectr."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13651501.2017.1397700","article-title":"Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study","author":"Wang","year":"2017","journal-title":"Int J Psychiatry Clin Pract."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e6598","DOI":"10.1371\/journal.pone.0006598","article-title":"Worth the 'EEfRT'? The effort expenditure for rewards task as an objective measure of motivation and anhedonia","volume":"4","author":"Treadway","year":"2009","journal-title":"PLoS ONE"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2019.00017\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T04:25:35Z","timestamp":1548908735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2019.00017\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":36,"alternative-id":["10.3389\/fpsyt.2019.00017"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2019.00017","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,31]]},"article-number":"17"}}